Lenz Therapeutics, Inc. (LENZ) — SEC Filings
Lenz Therapeutics, Inc. (LENZ) — 43 SEC filings. Latest: 4 (Mar 30, 2026). Includes 18 8-K, 5 10-Q, 4 SC 13G/A.
View Lenz Therapeutics, Inc. on SEC EDGAR
Overview
Lenz Therapeutics, Inc. (LENZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 30, 2026: On March 27, 2026, LENZ Therapeutics, Inc. (CIK: 0001815776) filed a Form 4 with the SEC, reporting changes in beneficial ownership of securities. The filing was accepted on March 30, 2026. The company is involved in the Biological Products sector.
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Lenz Therapeutics, Inc. is neutral.
Filing Type Overview
Lenz Therapeutics, Inc. (LENZ) has filed 3 4, 18 8-K, 5 10-Q, 1 DEF 14A, 2 10-K, 4 SC 13G/A, 2 SC 13D/A, 2 S-1, 4 SC 13G, 1 S-1/A, 1 SC 13D with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of LENZ's 31 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $12.5M |
| Net Income | -$16.7M |
| EPS | -$0.59 |
| Debt-to-Equity | 0.09 |
| Cash Position | $202.2M |
| Operating Margin | -151.1% |
| Total Assets | $210.7M |
| Total Debt | $16.8M |
Key Executives
- George Jeffrey P.
- Evert B. Schimmelpennink
- Chevallard Daniel R.
- Peter Kolchinsky
- Dr. Joshua Grass
Industry Context
The ophthalmic therapeutics market is characterized by significant R&D investment and a lengthy regulatory approval process. Companies often rely on strategic partnerships and licensing agreements to monetize their innovations. The recent FDA approval of VIZZ positions LENZ Therapeutics to compete in a market where effective treatments for specific eye conditions are in demand, but competition from established players and emerging therapies is intense.
Top Tags
8-K (6) · Biotechnology (6) · ownership-change (5) · financials (5) · biotech (5) · corporate-filing (4) · insider-filing (3) · sec-filing (3) · LENZ Therapeutics (3) · SEC Filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| License Revenue | $12.5M | First revenue reported for the three months ended September 30, 2025, up from $0 in prior year. |
| Net Loss (Q3 2025) | $16.7M | Increased from $10.2M in Q3 2024, indicating higher operating costs. |
| Net Loss (YTD 2025) | $46.2M | Increased from $37.1M in YTD 2024, reflecting ongoing investment. |
| SG&A Expenses (YTD 2025) | $51.5M | Significantly increased from $19.5M in YTD 2024, driven by VIZZ commercialization. |
| R&D Expenses (YTD 2025) | $18.7M | Decreased from $23.9M in YTD 2024, as focus shifts to commercialization. |
| Accumulated Deficit | $191.2M | As of September 30, 2025, highlighting historical losses. |
| Cash & Marketable Securities | $202.2M | As of September 30, 2025, providing liquidity for at least 12 months. |
| VIZZ FDA Approval Date | July 31, 2025 | Key milestone marking the transition to a commercial company. |
| SEC File Number | 001-40532 | Identifies the company's filing history with the SEC. |
| EIN | 84-4867570 | Employer Identification Number for tax purposes. |
| Revenue | $0 | No revenue for Q2 2025 or YTD 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | $35.2M | Increased from $25.1M in Q2 2024, reflecting higher operating expenses. |
| R&D Expenses (Q2 2025) | $28.5M | Up from $19.8M in Q2 2024, indicating increased investment in drug development. |
| G&A Expenses (Q2 2025) | $6.7M | Increased from $5.3M in Q2 2024, contributing to overall loss. |
| Cash & Equivalents | $250.0M | As of June 30, 2025, down from $300.0M at December 31, 2024, reflecting cash burn. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Lenz Therapeutics, Inc. (LENZ)?
Lenz Therapeutics, Inc. has 43 recent SEC filings from Feb 2024 to Mar 2026, including 18 8-K, 5 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LENZ filings?
Across 43 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Lenz Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lenz Therapeutics, Inc. (LENZ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lenz Therapeutics, Inc.?
Key financial highlights from Lenz Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LENZ?
The investment thesis for LENZ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lenz Therapeutics, Inc.?
Key executives identified across Lenz Therapeutics, Inc.'s filings include George Jeffrey P., Evert B. Schimmelpennink, Chevallard Daniel R., Peter Kolchinsky, Dr. Joshua Grass.
What are the main risk factors for Lenz Therapeutics, Inc. stock?
Of LENZ's 31 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Lenz Therapeutics, Inc.?
Forward guidance and predictions for Lenz Therapeutics, Inc. are extracted from SEC filings as they are enriched.